UNSPSC 51181548: Imirestat

This classification denotes an aldose reductase inhibitor with the molecular formula C15H8F2N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0PM69S95UQ, chemically known as 2,7-difluorospiro(fluorene-9,4-imidazolidine)-2,5-dione but generally known as imirestat, which bears US NIH Compound Identifier 65673. European Medicines Agency schedules Imirestat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08154MIG.

UNSPSC 51181548 Imirestat, a Commodity code, covers generic pharmaceutical products supplied through cooperative purchasing agreements to state and local government facilities. State and local governments buy imirestat and other generic multi-source pharmaceuticals through multistate cooperative purchasing vehicles that establish contracts with pharmaceutical manufacturers, requiring FDA compliance, cGMP and Drug Supply Chain Security Act certification, and distribution through authorized wholesalers. Issuing bodies include state purchasing offices administering cooperative purchasing alliances and their member jurisdictions across multiple states. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products serving participating state and local government facilities including Oregon. The RFP, due March 26, 2026, requires vendors to supply products with specific National Drug Codes through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with pricing evaluated at 75 percent weight and compliance with administrative fee requirements, EDI capability, and price competitiveness weighted at 5, 5, and 5 percent respectively, with fixed pricing comprising 10 percent of the evaluation. Contract terms run two years for new responders with optional MMCAP extensions, or align with existing expiration dates through June 30, 2028 for incumbent amendments, with awarded vendors taking effect July 1, 2026.

Recent solicitation activity concentrates in the upper Midwest through cooperative purchasing channels. MMCAP's January 2026 RFP represents the most recent documented opportunity under this code and signals active procurement for generic pharmaceutical supply across multistate networks. Vendors must maintain commercial general liability coverage of $5 million per occurrence, network security and privacy liability of $2 million, and professional liability of $2 million, with performance penalties ranging from $200 to $1,500 per violation for late reporting, missed onboarding, or improper class-of-trade denials, and all products must carry expiration dates of at least one year from manufacture with a minimum six-month shelf life.